Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive degradation of brain cells, as well ...

Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced that the first patient has been dosed in the company’s ...

Neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are medical conditions characterized by the progressive degradation ...

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA ...

With a new study in the journal Cell, researchers at Stanford University and Stockholm University have contributed to ...

Scientists have uncovered a genetic overlap between people and golden retrievers that helps explain why both species can be ...

The FDA has approved Novartis’ Itvisma (onasemnogene abeparvovec-brve) for the treatment of adolescents two years and older, teens, and adults living with spinal muscular atrophy (SMA) with a ...

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studiesOne-time dose of Itvisma replaces ...

As reported by the South China Morning Post ( SCMP ), the team found that the faeces of yaks, Tibetan sheep, antelope, cattle ...

A study by researchers at the University of Wisconsin–Madison has revealed a previously unknown pathway plants use to detect ...